Hoth to Concentrate on its Current Pipeline and Continue Phase 2 Clinical Study Hoth Has Over Twelve Months Cash on Balance Sheet NEW YORK, May 12, 2023 /PRNewswire/ — Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, today announced that they have…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.